In this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably, they identify a new “inflamed” subtype that may emerge following acquired chemoresistance but which may become more susceptible to immunotherapy.

中文翻译：

---

小细胞肺癌进入精准医疗时代

在本期《癌细胞》中，盖伊等人。描述了小细胞肺癌的分子分类，并扩展了先前的研究，强调了个性化治疗的潜力。值得注意的是，他们发现了一种新的“炎症”亚型，这种亚型可能在获得性化疗耐药后出现，但可能变得更容易受到免疫治疗的影响。